ExCulture develops an animal-free heparin substitute through mixed culture fermentation, addressing the ongoing shortages and challenges in the century-old heparin market. This biopharmaceutical solution aims to provide a reliable and efficient alternative to traditional heparin, enhancing global health outcomes.
Funding
$377.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The century-old heparin market faces ongoing shortages and significant challenges, potentially impacting global health outcomes due to its reliance on animal-derived sources. This dependence creates supply chain vulnerabilities and raises concerns about consistency and safety.
Solution
ExCulture is developing an animal-free heparin substitute produced through mixed culture fermentation. This novel biopharmaceutical solution aims to address the limitations of traditional heparin by providing a reliable, consistent, and ethically sourced alternative. By utilizing advanced fermentation techniques, ExCulture seeks to create a sustainable and scalable production process, ensuring a stable supply of heparin for critical medical applications. This innovative approach aims to mitigate the risks associated with animal-derived heparin, offering a safer and more dependable option for patients and healthcare providers.
Target Audience
The primary target audience includes pharmaceutical companies, hospitals, and healthcare providers seeking a reliable and ethically sourced alternative to traditional heparin.
Features
- Animal-free heparin substitute produced via mixed culture fermentation
- Addresses supply chain vulnerabilities associated with traditional heparin sources
- Aims to provide a more consistent and safer alternative to animal-derived heparin
- Sustainable and scalable production process through advanced fermentation techniques